Literature DB >> 17494640

Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.

Hui Hu1, Xinya Lu, Ling Tao, Bingke Bai, Zhenfeng Zhang, Yao Chen, Fangliang Zheng, Jianjun Chen, Ze Chen, Hanzhong Wang.   

Abstract

DNA vaccines induce humoral and cellular immune responses in animal models and humans. To analyze the immunogenicity of the severe acute respiratory syndrome (SARS) coronavirus (CoV), SARS-CoV, spike DNA vaccine and the immunoregulatory activity of interleukin-2 (IL-2), DNA vaccine plasmids pcDNA-S and pcDNA-IL-2 were constructed and inoculated into BALB/c mice with or without pcDNA-IL-2 by using three different immunization routes (the intramuscular route, electroporation, or the oral route with live attenuated Salmonella enterica serovar Typhimurium). The cellular and humoral immune responses were assessed by enzyme-linked immunosorbent assays, lymphocyte proliferation assays, enzyme-linked immunospot assays, and fluorescence-activated cell sorter analyses. The results showed that specific humoral and cellular immunities could be induced in mice by inoculating them with SARS-CoV spike DNA vaccine alone or by coinoculation with IL-2-expressing plasmids. In addition, the immune response levels in the coinoculation groups were significantly higher than those in groups receiving the spike DNA vaccine alone. The comparison between the three vaccination routes indicated that oral vaccination evoked a vigorous T-cell response and a weak response predominantly with subclass immunoglobulin G2a (IgG2a) antibody. However, intramuscular immunization evoked a vigorous antibody response and a weak T-cell response, and vaccination by electroporation evoked a vigorous response with a predominant subclass IgG1 antibody response and a moderate T-cell response. Our findings show that the spike DNA vaccine has good immunogenicity and can induce specific humoral and cellular immunities in BALB/c mice, while IL-2 plays an immunoadjuvant role and enhances the humoral and cellular immune responses. Different vaccination routes also evoke distinct immune responses. This study provides basic information for the design of DNA vaccines against SARS-CoV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17494640      PMCID: PMC1951058          DOI: 10.1128/CVI.00019-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

1.  Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.

Authors:  Dan H Barouch; Sampa Santra; Klara Tenner-Racz; Paul Racz; Marcelo J Kuroda; Joern E Schmitz; Shawn S Jackson; Michelle A Lifton; Dan C Freed; Helen C Perry; Mary-Ellen Davies; John W Shiver; Norman L Letvin
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

2.  Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

Authors:  S Zucchelli; S Capone; E Fattori; A Folgori; A Di Marco; D Casimiro; A J Simon; R Laufer; N La Monica; R Cortese; A Nicosia
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.

Authors:  J J Kim; J S Yang; K Dang; K H Manson; D B Weiner
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

4.  Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice.

Authors:  J Fló; S Tisminetzky; F Baralle
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

5.  Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.

Authors:  Anne C Moore; Wing-pui Kong; Bimal K Chakrabarti; Gary J Nabel
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice.

Authors:  I Nobiron; I Thompson; J Brownlie; M E Collins
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

7.  A crucial role of macrophages in the immune responses to oral DNA vaccination against hepatitis B virus in a murine model.

Authors:  B Zheng; P C Woo; M Ng; H Tsoi; L Wong; K Yuen
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

8.  Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.

Authors:  K Song; Y Chang; G J Prud'homme
Journal:  Gene Ther       Date:  2000-03       Impact factor: 5.250

9.  Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.

Authors:  P C Woo; L P Wong; B J Zheng; K Y Yuen
Journal:  Vaccine       Date:  2001-04-06       Impact factor: 3.641

10.  Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.

Authors:  Hong Zhang; Guangwen Wang; Jian Li; Yuchun Nie; Xuanling Shi; Gewei Lian; Wei Wang; Xiaolei Yin; Yang Zhao; Xiuxia Qu; Mingxiao Ding; Hongkui Deng
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more
  10 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.

Authors:  Lanying Du; Guangyu Zhao; Chris C S Chan; Lin Li; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

3.  Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.

Authors:  Baojing Lu; Yi Huang; Li Huang; Bao Li; Zhenhua Zheng; Ze Chen; Jianjun Chen; Qinxue Hu; Hanzhong Wang
Journal:  Immunology       Date:  2010-04-06       Impact factor: 7.397

Review 4.  The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.

Authors:  Nicholas A Wong; Milton H Saier
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 6.208

5.  Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.

Authors:  Lanying Du; Guangyu Zhao; Chris C S Chan; Shihui Sun; Min Chen; Zhonghua Liu; Hongxiang Guo; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Virology       Date:  2009-08-15       Impact factor: 3.616

Review 6.  Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.

Authors:  Atin Khalaj-Hedayati
Journal:  J Immunol Res       Date:  2020-07-18       Impact factor: 4.818

Review 7.  Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.

Authors:  Muhammad Bilal; Hafiz M N Iqbal
Journal:  Hum Vaccin Immunother       Date:  2020-08-26       Impact factor: 3.452

8.  Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model.

Authors:  Hui Hu; Xianqing Huang; Ling Tao; Yi Huang; Bao-An Cui; Hanzhong Wang
Journal:  Vaccine       Date:  2009-01-30       Impact factor: 3.641

Review 9.  Vaccines for COVID-19.

Authors:  J S Tregoning; E S Brown; H M Cheeseman; K E Flight; S L Higham; N-M Lemm; B F Pierce; D C Stirling; Z Wang; K M Pollock
Journal:  Clin Exp Immunol       Date:  2020-10-18       Impact factor: 4.330

Review 10.  Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases.

Authors:  Ziyang Xu; Ami Patel; Nicholas J Tursi; Xizhou Zhu; Kar Muthumani; Daniel W Kulp; David B Weiner
Journal:  Front Med Technol       Date:  2020-10-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.